Based on the feedback of our members, CARRA is increasing the funding amounts and project timelines for our small and large grants. Small grants are increasing from up to $25,000 for one year to up to $50,000 for two years and large grants are increasing from up to $50,000 over one year to up to $100,000 over two years! More details coming soon…
If you are planning to apply for the CARRA-Arthritis Foundation Small or Large Grants due October 1, 2020 please be aware:
For Applications Involving the CARRA Registry:
NEW REQUIREMENT FOR DATA ANALYSIS SUPPORT GRANTS
CARRA is looking for 3 more sites to join the CARRA Registry at this time. Interested sites should have the ability to access research coordinator and regulatory support and have a dedicated and engaged Principal Investigator (PI). The Registry PI must be a current CARRA member. If you have questions about the research coordinator responsibilities and effort required to participate in the CARRA Registry, please email our Research Coordinator Network leadership at [email protected]. For additional questions about participating in the CARRA Registry, please email [email protected]. Applications for the current cycle are due Monday, August 3. Click here to apply.
Laboratory studies have suggested that hydroxychloroquine (HCQ [Plaquenil]) can slow the growth of the 2019 coronavirus, however, it is unknown whether the doses of HCQ regularly given to pediatric patients with rheumatic diseases reach high enough levels to see this effect. A team of researchers, led by CARRA members Stephen Balevic and Laura Schanberg, sought to understand whether children who take HCQ to treat lupus have high enough levels in their blood to potentially slow the growth of the coronavirus.
The research team studied data and samples from CARRA’s APPLE Trial* and found that: 1) current HCQ dosing is unlikely to reach high enough levels in the blood to stop growth of the coronavirus and 2) high quality clinical trials are needed to determine whether the long-term doses of HCQ given to patients with rheumatic disease have any benefit in the setting of the coronavirus. See full article recently published in The Journal of Rheumatology here. This research was funded in part by a CARRA-Arthritis Foundation grant.
*CARRA’s APPLE trial (PIs Laura Schanberg, Christy Sandborg) remains the world’s largest clinical trial of pediatric lupus patients to date. The APPLE study was a prospective multicenter clinical trial of 221 children and adolescents with systemic lupus erythematosus (SLE). Data and biosamples were collected from patients 21 CARRA North American sites from 2003 to 2009 and remain available for ongoing research.
VERITY (Value and Evidence in Rheumatology using bioInformaTics, and advanced analYtics) is a NIAMS-funded P30 research program awarded to Brigham and Women’s Hospital. The 2020 VERITY course was held virtually Tuesday, May 12 through Friday, May 15 and was aimed at clinical investigators pursuing rheumatic disease epidemiologic and patient-oriented research. Attendees developed or refined a research protocol or specific aims for a grant proposal during the course.
Through a partnership with Brigham and Women’s Hospital and Harvard Medical School, CARRA was able to select one member to receive participate in the VERITY/Brigham Course at no cost. Funding for this award was provided by NIAMS. CARRA was pleased to select Patricia Vega Fernandez as the 2020 recipient for the full award.
“I highly recommend the VERITY course for those early investigators looking to enhance or develop the skills necessary to become a successful clinical and translational researcher… The best part of the course is the mentoring you received. I met with several mentors and peers who provided high quality feedback to improve my specific aims page and career goals in general.”
--Patricia Vega Fernandez, Cincinnati Children’s Hospital Medical Center
CARRA also selected additional members to receive partial sponsorship to participate in the virtual course. These awardees include Nicole Bitencourt, Jessica Bloom and John Bridges. To read about their experiences, click here.
We want to hear about YOU!
Utrecht Summer School Rescheduled for Virtual Session in October